VolitionRx Faces NYSE American Listing Non‑Compliance; Must Submit Remediation Plan by March 8, 2026

VolitionRx faces NYSE American compliance deadline after listing notice

VolitionRx Limited, a Belgium‑based epigenetics company, receives a notice from NYSE American that it is not meeting the exchange’s continued listing standards, triggering a formal remediation process. The notice, dated Feb. 6 and disclosed by the company on Feb. 9, cites non‑compliance with Section 1003(a)(i), (ii) and (iii) of the Company Guide relating to minimum stockholders’ equity thresholds tied to recent operating losses. The exchange also determines VolitionRx does not qualify for exemptions, including the $50 million market‑cap exemption.

The company must submit a plan by March 8, 2026 that explains steps taken or planned to regain compliance by Aug. 6, 2027, and NYSE American says it will subject an accepted plan to periodic reviews and quarterly monitoring. Failure to submit an acceptable plan, to make progress consistent with an accepted plan, or to achieve compliance by the deadline could prompt the exchange to initiate delisting proceedings under its rules; VolitionRx retains the right to appeal any staff delisting determination under Section 1010 and Part 12. NYSE American specifies that the notice has no immediate effect on the listing of the company’s common stock.

Industry observers and company stakeholders watch how management frames operational priorities while addressing governance and capital‑structure metrics. For VolitionRx, which develops epigenetics‑based diagnostic tests, the compliance notice places emphasis on corporate remediation rather than on altering its scientific pipeline: the company states its research programs, clinical activities and workforce continue unchanged while it engages with the exchange. Management must balance regulatory reporting, fundraising or restructuring options and ongoing development timelines for its biomarker assays during the remediation period.

Listing criteria and process details

NYSE American’s cited thresholds require minimum stockholders’ equity of $2.0 million if a company reports losses in two of its three most recent fiscal years, $4.0 million if losses occur in three of four years, and $6.0 million if losses occur in five recent years. The exchange notifies VolitionRx that it is not currently eligible for exemptions under Section 1003(a).

Company statement and next steps

VolitionRx emphasizes the notice does not affect day‑to‑day operations and that trading and corporate communications continue while it submits a remediation plan. The company faces a defined timeframe to show tangible progress and retains procedural rights to appeal any adverse staff action.